ClinicalTrials.gg
CompletedNCT01872715Updated Aug 23, 2022Results posted

Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea

A Phase 4 interventional study of Oracea in Papulopustular Rosacea, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 25 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-08-23.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
25 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing doxycycline in Rosacea — none open to participants now, 1 under way, none of them phase 3. Doxycycline · Rosacea.

Enrollment
11th of 12
24 · median 150
Started
2013
the only one that year
Phase 4
6 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
4 of 12
Galderma R&D

Among the 12 studies testing doxycycline in Rosacea, this one is the 11th largest by enrollment, is the only one that started in 2013, is one of 6 in phase 4, and was the 7th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 12 studies testing doxycycline in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About doxycycline

Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 25 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing doxycycline in Rosacea as a file.
02

Study summary

The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.

03

Conditions studied

  • Papulopustular Rosacea

Browse trials for

Keywords

  • Papulopustular Rosacea
  • Oracea
  • anti inflammatory doxycycline
04

Who can participate

Ages eligible
25 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women
  • 25-70 years
  • Diagnosis of papulopustular rosacea
  • Eligible for Oracea treatment

Exclusion criteria

Exclusion Criteria:

  • Allergies to components of product and/or to tetracyclines
  • Taken systemic therapy directed at improving rosacea, including antibiotics, within 30 days prior to baseline visit
  • Used topical rosacea treatment within 30 days prior to baseline visit
  • Have active ocular rosacea and/or blepharitis/meibomianitis requiring systemic treatment by an opthalmologist
  • Previously failed to have improvement of rosacea with appropriate use of systemic tetracycline family of antibiotics
  • Exposed to intense/excessive ultraviolet (UV) radiation within one week prior to baseline and/or who forsee unprotected and intense/excessive UV exposure during the course of the study
  • Have planned surgical procedures during the course of the study
  • Have used tetracycline antibiotics within 30 days prior to baseline visit or during study
  • At risk in terms of precautions, warnings, and
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Oracea

    Oracea (doxycycline USP, 40mg\[30mg immediate release/ 10mg delayed release beads\] taken once daily in the morning on an empty stomach, one hour before meals or two hours after. Oral dose for 12 weeks

    Drug: Oracea

Interventions

  • DrugOracea

    Also known as: doxycycline USP, 40 mg (30 mg immediate release/ 10 mg delayed release beads)

06

What researchers measure

Primary outcomes

  1. Rosacea Score on the Visual Analog Scale

    VAS = visual analog scale, 10 cm scale in which 0 = no rosacea, 10 = worst rosacea imaginable

    Time frame: Baseline, Weeks 2, 6, and 12

Secondary outcomes

  1. Rosacea-Specific Quality of Life Index

    ROSACEA-SPECIFIC QUALITY OF LIFE INDEX©: average of scores to 22 questions on a 5 point scale (1 = never, 5 = all the time)

    Time frame: Baseline, Weeks 2, 6, and 12

  2. Patient Global Assessment (PGA) of Rosacea Scores

    Patient Global Assessment (PGA) of Rosacea: 0 = clear, no signs or symptoms present; 1 = Near clear, 1 or 2 papules; 2 = mild, some (3 to 10) papules/pustules; 3 = moderate, moderate (11 to 19) number of papules and pustules; 4 = severe, numerous (≥ 20) papules/pustules; nodules

    Time frame: Baseline, Weeks 2, 6, and 12

  3. Patient Satisfaction Question

    The patient satisfaction question was answered by the subject at week 2, week 6, and week 12. The subject was asked how satisfied they were with this treatment (doxycycline MR) for rosacea.

    Time frame: Week 2, 6, and 12

07

Results

Posted Feb 15, 2016

Participant flow

Participant flow — Overall Study
MilestoneOracea
Started24
Completed20
Not completed4
Withdrew: Adverse event1
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryRosacea Score on the Visual Analog Scale

VAS = visual analog scale, 10 cm scale in which 0 = no rosacea, 10 = worst rosacea imaginable

Time frame:
Baseline, Weeks 2, 6, and 12
Reported as:
Mean · units on a scale
Rosacea Score on the Visual Analog Scale
units on a scaleOracea
Baseline4.50 ± 1.81
Week 24.52 ± 1.87
Week 63.77 ± 1.93
Week 123.06 ± 2.34
SecondaryRosacea-Specific Quality of Life Index

ROSACEA-SPECIFIC QUALITY OF LIFE INDEX©: average of scores to 22 questions on a 5 point scale (1 = never, 5 = all the time)

Time frame:
Baseline, Weeks 2, 6, and 12
Reported as:
Mean · units on a scale
Rosacea-Specific Quality of Life Index
units on a scaleOracea
Baseline3.34 ± 0.55
Week 23.07 ± 0.56
Week 62.89 ± 0.81
Week 122.85 ± 0.86
SecondaryPatient Global Assessment (PGA) of Rosacea Scores

Patient Global Assessment (PGA) of Rosacea: 0 = clear, no signs or symptoms present; 1 = Near clear, 1 or 2 papules; 2 = mild, some (3 to 10) papules/pustules; 3 = moderate, moderate (11 to 19) number of papules and pustules; 4 = severe, numerous (≥ 20) papules/pustules; nodules

Time frame:
Baseline, Weeks 2, 6, and 12
Reported as:
Number · participants
Patient Global Assessment (PGA) of Rosacea Scores
participants0 = Clear1 = Near Clear2 = Mild3 = Moderate4 = Severe
Baseline011740
Week 2041620
Week 60101110
Week 12314410
SecondaryPatient Satisfaction Question

The patient satisfaction question was answered by the subject at week 2, week 6, and week 12. The subject was asked how satisfied they were with this treatment (doxycycline MR) for rosacea.

Time frame:
Week 2, 6, and 12
Reported as:
Number · participants
Patient Satisfaction Question
participantsVery SatisfiedSatisfiedNeither Satisfied Nor DissatisfiedDissatisfiedVery Dissatisfied
Week 2111820
Week 647821
Week 1286521

Adverse events

Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oracea—0/24 (0%)7/24 (29.2%)
Most frequent other events
Most frequent other events
EventOracea
VomitingGastrointestinal disorders3/24
DiarrheaGastrointestinal disorders2/24
CoughRespiratory, thoracic and mediastinal disorders2/24

Baseline characteristics

Safety population

Age, Continuous
Age, Continuous(years)Oracea
Mean53.04 ± 11.02
Sex: Female, Male
Sex: Female, Male(Participants)Oracea
Female1
Male23
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Oracea
Hispanic or Latino3
Not Hispanic or Latino21
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oracea
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White24
More than one race0
Unknown or Not Reported0
Years since the first rosacea diagnosis
Years since the first rosacea diagnosis(years)Oracea
Mean5.75 ± 8.36
Skin type
Skin type(participants)Oracea
Dry8
Normal4
Oily1
Combination11
Fistzpatrick Skin Type
Fistzpatrick Skin Type(participants)Oracea
I2
II15
III5
IV2
V0
VI0
08

Study locations

1 site
  • Stephens & Associates Dallas Research Center
    Carrollton, Texas 75006, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2013
First posted
Jun 7, 2013
Start
Mar 2013
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Feb 15, 2016
Last update
Aug 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01872715
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jun 7, 2013
Start date
Mar 2013
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Feb 15, 2016
Last update
Aug 23, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxycycline

Start the discussion